Pins matching tag:Cologuard

Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.

Abbott closed its $105-a-share cash purchase of Cologuard maker Exact Sciences, which became a wholly owned Abbott subsidiary; Exact Sciences shares last traded on Nasdaq on 20 March.

Abbott posted second-quarter sales of $12.59 billion, up 13.0% reported and 4.8% comparable, and adjusted EPS of $1.31, and raised its 2026 adjusted EPS guidance to $5.45 to $5.60.

Abbott reported US$13.013 billion in third-quarter sales, up 14.5%, and adjusted diluted EPS of US$1.42. It forecasts about 6% comparable sales growth for 2026 and tightened adjusted EPS guidance to US$5.50–5.55.